Kopmar, N. E., Fromm, J. R., Pinke, N., Martino, C., Sherrow, A., Ghiuzeli, C. M., Mawad, R., Gooley, T., Cooper, J. P., Kimble, E. L., Scott, B. L., Hendrie, P., Orozco, J. J., Veatch, J., Percival, M. M., Cassaday, R. D. (2025). Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) for adults with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.6540